Influence of cytomegalovims seropositivity on outcome after T cell-depleted bone marrow transplantation: Contrasting results between recipients of grafts from related and unrelated donors

Clinical Infectious Diseases

Volumn 35, Issue 6, 2002, Pages 703-712

  Meijer, Ellen ^a   Dekker, Adriaan W ^a   Rozenberg Arska, Maja ^b   Weersink, Annemarie J L ^b   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GASTRITIS; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; SERODIAGNOSIS; STATISTICAL ANALYSIS; STEROID THERAPY; VIRUS ENCEPHALITIS; VIRUS PNEUMONIA; WHOLE BODY RADIATION; BLOOD DONOR; CHEMOPROPHYLAXIS; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; SURVIVAL RATE; T LYMPHOCYTE; TRANSPLANTATION;

ADOLESCENT; ADULT; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTS;

EID: 0037104965     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342332     Document Type: Article

References (29)

1. Risk factors for cytomegalovirus infection after human marrow transplantation
2. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
3. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation
4. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters
5. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation
6. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
7. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
8. Ganciclovir prophylaxis of cytomegalovirus infection in allogeneic bone marrow transplant recipients
9. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
10. A risk adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplantation
11. Bone marrow transplantation
12. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft
13. Rapid detection of infectious cytomegalovirus in blood with aid of monoclonal antibodies
14. Rapid immunodiagnosis of active cytomegalovirus infection by monodonal antibody staining of blood leukocytes
15. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells
16. The depletion of T cells from haematopoietic stem cell transplants
17. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T-cell depletion technique
18. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants
19. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
20. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV) - Seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection
21. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with antithymocyte globulin
22. Unrelated marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the national marrow donor program
23. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
24. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis
25. Donor CMV serostatus influences outcome after unrelated donor stem cell transplantation: An EBMT megafile analysis
26. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
27. Recovery of HLA-restricted cytomegalovirus (CVM) - Specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
28. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells
29. Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation?